Metabolic support with perhexiline for myocardium protection in patients undergoing coronary artery surgery.

Trial Profile

Metabolic support with perhexiline for myocardium protection in patients undergoing coronary artery surgery.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Perhexiline (Primary)
  • Indications Myocardial ischaemia; Myocardial reperfusion injury
  • Focus Therapeutic Use
  • Acronyms CASPER
  • Most Recent Events

    • 16 Sep 2015 Subgroup results (stereoselective handling of perhexiline) published in the European Journal of Clinical Pharmacology.
    • 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
    • 20 May 2010 Planned end date changed from 29 Jan 2010 to 13 Apr 2010 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top